Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

A murine model of diarrhea, growth impairment and metabolic disturbances with Shigella flexneri infection and the role of zinc deficiency.

Q S Medeiros PH, Ledwaba SE, Bolick DT, Giallourou N, Yum LK, Costa DVS, Oriá RB, Barry EM, Swann JR, Lima AÂM, Agaisse H, Guerrant RL.

Gut Microbes. 2019 Feb 3:1-16. doi: 10.1080/19490976.2018.1564430. [Epub ahead of print]

PMID:
30712505
2.

Evaluating S. flexneri pathogenesis in the human enteroid model.

Ranganathan S, Doucet M, Grassel CL, Delaine-Elias B, Zachos NC, Barry EM.

Infect Immun. 2019 Jan 14. pii: IAI.00740-18. doi: 10.1128/IAI.00740-18. [Epub ahead of print]

3.

Correction for Giuntini et al., "Identification and Characterization of Human Monoclonal Antibodies for Immunoprophylaxis against Enterotoxigenic Escherichia coli Infection".

Giuntini S, Stoppato M, Sedic M, Ejemel M, Pondish JR, Wisheart D, Schiller ZA, Thomas WD Jr, Barry EM, Cavacini LA, Klempner MS, Wang Y.

Infect Immun. 2018 Nov 20;86(12). pii: e00713-18. doi: 10.1128/IAI.00713-18. Print 2018 Dec. No abstract available.

4.

Aerosol prime-boost vaccination provides strong protection in outbred rabbits against virulent type A Francisella tularensis.

O'Malley KJ, Bowling JL, Stinson E, Cole KS, Mann BJ, Namjoshi P, Hazlett KRO, Barry EM, Reed DS.

PLoS One. 2018 Oct 22;13(10):e0205928. doi: 10.1371/journal.pone.0205928. eCollection 2018. Erratum in: PLoS One. 2018 Nov 15;13(11):e0207721.

5.

White and infrared light continuous photobioreactors for resource recovery from poultry processing wastewater - A comparison.

Hülsen T, Hsieh K, Tait S, Barry EM, Puyol D, Batstone DJ.

Water Res. 2018 Nov 1;144:665-676. doi: 10.1016/j.watres.2018.07.040. Epub 2018 Jul 17.

PMID:
30096692
6.

A Novel Shigella Proteome Microarray Discriminates Targets of Human Antibody Reactivity following Oral Vaccination and Experimental Challenge.

Ndungo E, Randall A, Hazen TH, Kania DA, Trappl-Kimmons K, Liang X, Barry EM, Kotloff KL, Chakraborty S, Mani S, Rasko DA, Pasetti MF.

mSphere. 2018 Aug 1;3(4). pii: e00260-18. doi: 10.1128/mSphere.00260-18.

7.

Identification and Characterization of Human Monoclonal Antibodies for Immunoprophylaxis Against Enterotoxigenic Escherichia coli Infection.

Giuntini S, Stoppato M, Sedic M, Ejemel M, Pondish JR, Wisheart D, Schiller ZA, Thomas WD Jr, Barry EM, Cavacini LA, Klempner MS, Wang Y.

Infect Immun. 2018 Jun 4. pii: IAI.00355-18. doi: 10.1128/IAI.00355-18. [Epub ahead of print] Erratum in: Infect Immun. 2018 Nov 20;86(12):.

8.

The Critical Role of Zinc in a New Murine Model of Enterotoxigenic E. coli (ETEC) Diarrhea.

Bolick DT, Medeiros PHQS, Ledwaba SE, Lima AAM, Nataro JP, Barry EM, Guerrant RL.

Infect Immun. 2018 Apr 16. pii: IAI.00183-18. doi: 10.1128/IAI.00183-18. [Epub ahead of print]

9.

Deletion of the Major Facilitator Superfamily Transporter fptB Alters Host Cell Interactions and Attenuates Virulence of Type A Francisella tularensis.

Balzano PM, Cunningham AL, Grassel C, Barry EM.

Infect Immun. 2018 Feb 20;86(3). pii: e00832-17. doi: 10.1128/IAI.00832-17. Print 2018 Mar.

10.

Differential Growth of Francisella tularensis, Which Alters Expression of Virulence Factors, Dominant Antigens, and Surface-Carbohydrate Synthases, Governs the Apparent Virulence of Ft SchuS4 to Immunized Animals.

Holland KM, Rosa SJ, Kristjansdottir K, Wolfgeher D, Franz BJ, Zarrella TM, Kumar S, Sunagar R, Singh A, Bakshi CS, Namjoshi P, Barry EM, Sellati TJ, Kron SJ, Gosselin EJ, Reed DS, Hazlett KRO.

Front Microbiol. 2017 Jun 22;8:1158. doi: 10.3389/fmicb.2017.01158. eCollection 2017.

11.

Bioactive Immune Components of Anti-Diarrheagenic Enterotoxigenic Escherichia coli Hyperimmune Bovine Colostrum Products.

Sears KT, Tennant SM, Reymann MK, Simon R, Konstantopoulos N, Blackwelder WC, Barry EM, Pasetti MF.

Clin Vaccine Immunol. 2017 Aug 4;24(8). pii: e00186-16. doi: 10.1128/CVI.00186-16. Print 2017 Aug.

12.

Analysis of Shigella flexneri Resistance, Biofilm Formation, and Transcriptional Profile in Response to Bile Salts.

Nickerson KP, Chanin RB, Sistrunk JR, Rasko DA, Fink PJ, Barry EM, Nataro JP, Faherty CS.

Infect Immun. 2017 May 23;85(6). pii: e01067-16. doi: 10.1128/IAI.01067-16. Print 2017 Jun.

13.

A mechanistic model for anaerobic phototrophs in domestic wastewater applications: Photo-anaerobic model (PAnM).

Puyol D, Barry EM, Hülsen T, Batstone DJ.

Water Res. 2017 Jun 1;116:241-253. doi: 10.1016/j.watres.2017.03.022. Epub 2017 Mar 9.

PMID:
28347950
14.

Monophosphoryl Lipid A Enhances Efficacy of a Francisella tularensis LVS-Catanionic Nanoparticle Subunit Vaccine against F. tularensis Schu S4 Challenge by Augmenting both Humoral and Cellular Immunity.

Richard K, Mann BJ, Qin A, Barry EM, Ernst RK, Vogel SN.

Clin Vaccine Immunol. 2017 Mar 6;24(3). pii: e00574-16. doi: 10.1128/CVI.00574-16. Print 2017 Mar.

15.

The synthesis of OspD3 (ShET2) in Shigella flexneri is independent of OspC1.

Faherty CS, Wu T, Morris CR, Grassel CL, Rasko DA, Harper JM, Shea-Donohue T, Fasano A, Barry EM.

Gut Microbes. 2016 Nov;7(6):486-502. Epub 2016 Sep 22.

16.

Genomic diversity of EPEC associated with clinical presentations of differing severity.

Hazen TH, Donnenberg MS, Panchalingam S, Antonio M, Hossain A, Mandomando I, Ochieng JB, Ramamurthy T, Tamboura B, Qureshi S, Quadri F, Zaidi A, Kotloff KL, Levine MM, Barry EM, Kaper JB, Rasko DA, Nataro JP.

Nat Microbiol. 2016 Jan 18;1:15014. doi: 10.1038/nmicrobiol.2015.14.

17.

Respiratory and oral vaccination improves protection conferred by the live vaccine strain against pneumonic tularemia in the rabbit model.

Stinson E, Smith LP, Cole KS, Barry EM, Reed DS.

Pathog Dis. 2016 Oct;74(7). pii: ftw079. doi: 10.1093/femspd/ftw079. Epub 2016 Aug 9.

18.

Low temperature treatment of domestic wastewater by purple phototrophic bacteria: Performance, activity, and community.

Hülsen T, Barry EM, Lu Y, Puyol D, Batstone DJ.

Water Res. 2016 Sep 1;100:537-545. doi: 10.1016/j.watres.2016.05.054. Epub 2016 May 19.

PMID:
27235774
19.

Domestic wastewater treatment with purple phototrophic bacteria using a novel continuous photo anaerobic membrane bioreactor.

Hülsen T, Barry EM, Lu Y, Puyol D, Keller J, Batstone DJ.

Water Res. 2016 Sep 1;100:486-495. doi: 10.1016/j.watres.2016.04.061. Epub 2016 Apr 29.

PMID:
27232993
20.

Characterization of a multicomponent live, attenuated Shigella flexneri vaccine.

DeLaine BC, Wu T, Grassel CL, Shimanovich A, Pasetti MF, Levine MM, Barry EM.

Pathog Dis. 2016 Jul;74(5). pii: ftw034. doi: 10.1093/femspd/ftw034. Epub 2016 Apr 21.

21.

Simple method for purification of enterotoxigenic Escherichia coli fimbriae.

Curtis B, Grassel C, Laufer RS, Sears KT, Pasetti MF, Barry EM, Simon R.

Protein Expr Purif. 2016 Mar;119:130-5. doi: 10.1016/j.pep.2015.11.007. Epub 2015 Nov 12.

22.

Characterization of Francisella tularensis Schu S4 defined mutants as live-attenuated vaccine candidates.

Santiago AE, Mann BJ, Qin A, Cunningham AL, Cole LE, Grassel C, Vogel SN, Levine MM, Barry EM.

Pathog Dis. 2015 Aug;73(6):ftv036. doi: 10.1093/femspd/ftv036. Epub 2015 May 17.

23.

Gut-Homing Conventional Plasmablasts and CD27(-) Plasmablasts Elicited after a Short Time of Exposure to an Oral Live-Attenuated Shigella Vaccine Candidate in Humans.

Toapanta FR, Simon JK, Barry EM, Pasetti MF, Levine MM, Kotloff KL, Sztein MB.

Front Immunol. 2014 Aug 20;5:374. doi: 10.3389/fimmu.2014.00374. eCollection 2014.

24.

Shigella isolates from the global enteric multicenter study inform vaccine development.

Livio S, Strockbine NA, Panchalingam S, Tennant SM, Barry EM, Marohn ME, Antonio M, Hossain A, Mandomando I, Ochieng JB, Oundo JO, Qureshi S, Ramamurthy T, Tamboura B, Adegbola RA, Hossain MJ, Saha D, Sen S, Faruque AS, Alonso PL, Breiman RF, Zaidi AK, Sur D, Sow SO, Berkeley LY, O'Reilly CE, Mintz ED, Biswas K, Cohen D, Farag TH, Nasrin D, Wu Y, Blackwelder WC, Kotloff KL, Nataro JP, Levine MM.

Clin Infect Dis. 2014 Oct;59(7):933-41. doi: 10.1093/cid/ciu468. Epub 2014 Jun 23.

25.

Live attenuated mutants of Francisella tularensis protect rabbits against aerosol challenge with a virulent type A strain.

Reed DS, Smith LP, Cole KS, Santiago AE, Mann BJ, Barry EM.

Infect Immun. 2014 May;82(5):2098-105. doi: 10.1128/IAI.01498-14. Epub 2014 Mar 10.

26.

Novel catanionic surfactant vesicle vaccines protect against Francisella tularensis LVS and confer significant partial protection against F. tularensis Schu S4 strain.

Richard K, Mann BJ, Stocker L, Barry EM, Qin A, Cole LE, Hurley MT, Ernst RK, Michalek SM, Stein DC, Deshong P, Vogel SN.

Clin Vaccine Immunol. 2014 Feb;21(2):212-26. doi: 10.1128/CVI.00738-13. Epub 2013 Dec 18.

27.

Live attenuated tularemia vaccines: recent developments and future goals.

Marohn ME, Barry EM.

Vaccine. 2013 Aug 2;31(35):3485-91. doi: 10.1016/j.vaccine.2013.05.096. Epub 2013 Jun 10. Review.

28.

Characterization of intracellular growth regulator icgR by utilizing transcriptomics to identify mediators of pathogenesis in Shigella flexneri.

Morris CR, Grassel CL, Redman JC, Sahl JW, Barry EM, Rasko DA.

Infect Immun. 2013 Sep;81(9):3068-76. doi: 10.1128/IAI.00537-13. Epub 2013 Jun 10.

29.

Progress and pitfalls in Shigella vaccine research.

Barry EM, Pasetti MF, Sztein MB, Fasano A, Kotloff KL, Levine MM.

Nat Rev Gastroenterol Hepatol. 2013 Apr;10(4):245-55. doi: 10.1038/nrgastro.2013.12. Epub 2013 Feb 19. Review.

30.

Chromosomal and plasmid-encoded factors of Shigella flexneri induce secretogenic activity ex vivo.

Faherty CS, Harper JM, Shea-Donohue T, Barry EM, Kaper JB, Fasano A, Nataro JP.

PLoS One. 2012;7(11):e49980. doi: 10.1371/journal.pone.0049980. Epub 2012 Nov 16. Erratum in: PLoS One. 2013;8(5). doi:10.1371/annotation/44400281-2456-4853-a89b-4dea4f9aa27b. Faherty, Christina [corrected to Faherty, Christina S].

31.

Shigella flexneri effectors OspE1 and OspE2 mediate induced adherence to the colonic epithelium following bile salts exposure.

Faherty CS, Redman JC, Rasko DA, Barry EM, Nataro JP.

Mol Microbiol. 2012 Jul;85(1):107-21. doi: 10.1111/j.1365-2958.2012.08092.x. Epub 2012 May 23.

32.

Members of the Francisella tularensis phagosomal transporter subfamily of major facilitator superfamily transporters are critical for pathogenesis.

Marohn ME, Santiago AE, Shirey KA, Lipsky M, Vogel SN, Barry EM.

Infect Immun. 2012 Jul;80(7):2390-401. doi: 10.1128/IAI.00144-12. Epub 2012 Apr 16.

33.

Live attenuated Shigella dysenteriae type 1 vaccine strains overexpressing shiga toxin B subunit.

Wu T, Grassel C, Levine MM, Barry EM.

Infect Immun. 2011 Dec;79(12):4912-22. doi: 10.1128/IAI.05814-11. Epub 2011 Oct 3.

34.

Formulation and stabilization of Francisella tularensis live vaccine strain.

Ohtake S, Martin RA, Saxena A, Lechuga-Ballesteros D, Santiago AE, Barry EM, Truong-Le V.

J Pharm Sci. 2011 Aug;100(8):3076-3087. doi: 10.1002/jps.22563. Epub 2011 Apr 13.

35.

Shigella enterotoxin-2 is a type III effector that participates in Shigella-induced interleukin 8 secretion by epithelial cells.

Farfán MJ, Toro CS, Barry EM, Nataro JP.

FEMS Immunol Med Microbiol. 2011 Apr;61(3):332-9. doi: 10.1111/j.1574-695X.2011.00778.x. Epub 2011 Feb 2.

36.

Vaccines against tularemia.

Barry EM, Cole LE, Santiago AE.

Hum Vaccin. 2009 Dec;5(12):832-8. Epub 2009 Dec 11. Review.

37.

Vaccination of children in low-resource countries against Shigella is unlikely to present an undue risk of reactive arthritis.

Gaston JS, Inman RD, Ryan ET, Venkatesan MM, Barry EM, Hale TL, Bourgeois AL, Walker RI.

Vaccine. 2009 Sep 4;27(40):5432-4. doi: 10.1016/j.vaccine.2009.06.107. Epub 2009 Jul 28.

PMID:
19643213
38.

Characterization of rationally attenuated Francisella tularensis vaccine strains that harbor deletions in the guaA and guaB genes.

Santiago AE, Cole LE, Franco A, Vogel SN, Levine MM, Barry EM.

Vaccine. 2009 Apr 21;27(18):2426-36. doi: 10.1016/j.vaccine.2009.02.073. Epub 2009 Mar 3.

39.

CfaE tip mutations in enterotoxigenic Escherichia coli CFA/I fimbriae define critical human intestinal binding sites.

Baker KK, Levine MM, Morison J, Phillips A, Barry EM.

Cell Microbiol. 2009 May;11(5):742-54. doi: 10.1111/j.1462-5822.2009.01287.x. Epub 2009 Jan 15.

40.
41.

Preclinical safety and biodistribution of Sindbis virus measles DNA vaccines administered as a single dose or followed by live attenuated measles vaccine in a heterologous prime-boost regimen.

Ramirez K, Barry EM, Ulmer J, Stout R, Szabo J, Manetz S, Levine MM, Pasetti MF.

Hum Gene Ther. 2008 May;19(5):522-31. doi: 10.1089/hum.2007.172.

PMID:
18507515
42.

Heterologous prime-boost strategy to immunize very young infants against measles: pre-clinical studies in rhesus macaques.

Pasetti MF, Resendiz-Albor A, Ramirez K, Stout R, Papania M, Adams RJ, Polack FP, Ward BJ, Burt D, Chabot S, Ulmer J, Barry EM, Levine MM.

Clin Pharmacol Ther. 2007 Dec;82(6):672-85. Epub 2007 Oct 31.

PMID:
17971812
43.

Safety and immunogenicity of CVD 1208S, a live, oral DeltaguaBA Deltasen Deltaset Shigella flexneri 2a vaccine grown on animal-free media.

Kotloff KL, Simon JK, Pasetti MF, Sztein MB, Wooden SL, Livio S, Nataro JP, Blackwelder WC, Barry EM, Picking W, Levine MM.

Hum Vaccin. 2007 Nov-Dec;3(6):268-75. Epub 2007 Jul 15.

PMID:
17938573
44.

Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road.

Levine MM, Kotloff KL, Barry EM, Pasetti MF, Sztein MB.

Nat Rev Microbiol. 2007 Jul;5(7):540-53. Review.

45.

Patient satisfaction after medial opening high tibial osteotomy and microfracture.

Miller BS, Joseph TA, Barry EM, Rich VJ, Sterett WI.

J Knee Surg. 2007 Apr;20(2):129-33.

PMID:
17486904
46.
47.

Immunogenicity of multivalent Shigella-ETEC candidate vaccine strains in a guinea pig model.

Barry EM, Wang J, Wu T, Davis T, Levine MM.

Vaccine. 2006 May 1;24(18):3727-34. Epub 2005 Jul 22.

PMID:
16169130
48.

Characterization of immune responses induced by intramuscular vaccination with DNA vaccines encoding measles virus hemagglutinin and/or fusion proteins.

Song MK, Vindurampulle CJ, Capozzo AV, Ulmer J, Polo JM, Pasetti MF, Barry EM, Levine MM.

J Virol. 2005 Aug;79(15):9854-61.

49.

Deletion in the Shigella enterotoxin genes further attenuates Shigella flexneri 2a bearing guanine auxotrophy in a phase 1 trial of CVD 1204 and CVD 1208.

Kotloff KL, Pasetti MF, Barry EM, Nataro JP, Wasserman SS, Sztein MB, Picking WD, Levine MM.

J Infect Dis. 2004 Nov 15;190(10):1745-54. Epub 2004 Oct 19. Erratum in: J Infect Dis. 2005 Jun 15;191(12):2161.

PMID:
15499528
50.

Recombinant Salmonella enterica serovar Typhi in a prime-boost strategy.

Vindurampulle CJ, Cuberos LF, Barry EM, Pasetti MF, Levine MM.

Vaccine. 2004 Sep 9;22(27-28):3744-50.

PMID:
15315855

Supplemental Content

Loading ...
Support Center